CN1579523A - Infant's Runtu granulars and preparation method - Google Patents
Infant's Runtu granulars and preparation method Download PDFInfo
- Publication number
- CN1579523A CN1579523A CN 200410042525 CN200410042525A CN1579523A CN 1579523 A CN1579523 A CN 1579523A CN 200410042525 CN200410042525 CN 200410042525 CN 200410042525 A CN200410042525 A CN 200410042525A CN 1579523 A CN1579523 A CN 1579523A
- Authority
- CN
- China
- Prior art keywords
- parts
- volatile oil
- powder
- fry
- stir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 239000000341 volatile oil Substances 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 26
- 241000208340 Araliaceae Species 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 241001127714 Amomum Species 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims abstract description 3
- 230000002687 intercalation Effects 0.000 claims description 24
- 238000009830 intercalation Methods 0.000 claims description 24
- 239000002689 soil Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 10
- 238000005538 encapsulation Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- -1 filters Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 235000011837 pasties Nutrition 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000001256 steam distillation Methods 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000007908 dry granulation Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 239000004615 ingredient Substances 0.000 abstract description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 4
- 239000011505 plaster Substances 0.000 abstract 4
- 241000132012 Atractylodes Species 0.000 abstract 3
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 3
- 244000197580 Poria cocos Species 0.000 abstract 3
- 235000008599 Poria cocos Nutrition 0.000 abstract 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 241000234653 Cyperus Species 0.000 abstract 2
- 235000002848 Cyperus flabelliformis Nutrition 0.000 abstract 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 2
- 235000011477 liquorice Nutrition 0.000 abstract 2
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 description 10
- 239000003643 water by type Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 3
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a children runtu particles prescription and its manufacturing method. The particle is made up of ingredients with following proportion: ginseng 250-320, lagehead atractylodes 160-220, Tuckahoe 160-220, dried tangerine peel 200-270, nutagrass flatsedge rhizome 200-270, malt 200-270, hawthorn 200-270, amomum fruit 200-270, liquorice 100-180. the lagehead atractylodes, lagehead atractylodes, nutagrass flatsedge rhizome and amonum fruit are crashed into raw powder, extracts the volatile oil with steam distilling method. The dredge is blended with Tuckahoe, malt, hawthorn, liquorice and they are stewed, filtered, the filtered liquid is merged with water liquid after the oil is extracted, then they are condensed into plaster. The ginseng is crashed into raw powder, then adds in alcohol to carry on secondary extraction, combines the extracted liquids, filters and reclaims alcohol, and then they are condensed into plaster. It is combined with Tuckahoe, then they are dried, and crashed into dry extract plaster powder. The volatile oil is packaged with beta-cyclodextrin, low temperature dried, crashed, and blended with extractive plaster powder. The product can be acquired through adding in some cane sugar powder.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation prescription and preparation method thereof, intercalation soil particle prescription of particularly a kind of children's and preparation method thereof.
Background technology
Infantile gastritis is meant because physical property, chemical and biological injurious factor act on human body, causes a kind of disease that gastric mucosa is inflamed and sexually revises.Clinically be divided into acute and chronic two kinds, mainly be meant chronic infantile gastritis here.The cause of disease and pathogeny are not clear fully as yet, may be relevant with following factor: stressors, drug induced gastritis, albumen allergy, infection etc.Clinical manifestation based on stomachache, abdominal distention, belch, inappetence, nausea and vomiting, unable, become thin etc.Pathological change is based on the infringement of gastric mucosa shallow, and the treatment aspect does not have specific treatment, mainly is anti symptom treatment, as gives mucosa protective agent, histamine H 2 receptor's blocker, anti-helicobacter pylori medicine etc.
The research of Chinese medicine bound pair infantile gastritis report is less over past ten years, may be because of the restriction of subject, and make the disease that internal medicine and other clinical specialities are compared in its research want much less.And the overwhelming majority all is the research at treatment side's medicine.Still based on coloclysis and oral decoction, this causes inconvenience to the patient to children's's clinical application.Though occurred granule, tablet and capsule in the report in recent years, for number is still few, and be former powder formulation, dose is big, and bioavailability is low.If extract effective ingredient or effective site in compound recipe or the medicine, or be that raw material then can significantly reduce dose with the extract powder.Consider these aspects, preparation research and improvement become one of primary study direction of infantile gastritis.
This prescription be national distinguished veteran doctors of TCM Mr. Zhang Zhenyu learn something in history the people method, melt treatment children's chronic gastritis that self reason foundes through proved recipe.This side utilize natural drug abnormal smells from the patient, return through characteristics such as, lifting sink-floats, transfer the mediation ability of human body self, the inherent more pathogenesis system of exciting human, remedying defects and rectifying errors is not controlled inflammation and scorching spontaneous recovery on the whole.And the characteristics that this product is tender and lovely at children's's internal organs, shape gas does not fill, strengthening vital QI to eliminate pathogenic factors all adopt gentle product, and are eliminating evil and just do not hinder, and set upright and do not stay heresy.As the potent activating QI to eliminate phlegm medicines such as summer, the Radix Aucklandiae that reduce by half among the former side, and add with gentle medicines of regulating the flow of vital energy such as Rhizoma Cyperi, Fructus Citris.But up to now, also only rest on the clinical treatment of prescription, do not see that the Chinese patent medicine preparation that this prescription is arranged comes out.
The present invention makes a kind of Chinese patent medicine preparation on the basis of above-mentioned prescription, be that the intercalation soil particle of children's of main effective ingredient has invigorating the spleen and regulating the stomach with Radix Ginseng, and removing dampness disappears stagnant, promoting the circulation of QI to relieve pain.Be used for infantile gastritis, because of intemperance of taking food, syndrome of incoordination between spleen and stomach due to the taste abnormal ascending-descending of QI.Card is seen stomachache, feels sick, and pantothenic acid, abdominal distention, indigestion and loss of appetite, fatigue and weakness, light red tongue, greasy fur, arteries and veins or slow.The intercalation soil particle treatment of children's has obtained obvious effects, and the prescription of this medicament and preparation technology can produce bigger influence to the quality and the curative effect of medicine.
Summary of the invention
The object of the present invention is to provide the intercalation soil particle of a kind of children's, the intercalation native preparation of children's is made graininess, be used to take after mixing it with water.Its effective ingredient can reach at utmost and keep.
The present invention also aims to provide a kind of preparation method of above-mentioned granular preparation.
The prescription of the intercalation soil particle of children's of the present invention is: Radix Ginseng, the Rhizoma Atractylodis Macrocephalae (stir-fry), Poria, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Fructus Hordei Germinatus (stir-fry), Fructus Crataegi (Jiao), Fructus Amomi, Radix Glycyrrhizae.
Specifically each the tcm components processing and preparing by the following weight ratio forms:
250～320 parts of Radix Ginsengs
160～220 parts of the Rhizoma Atractylodis Macrocephalaes (stir-fry)
160～220 parts in Poria
200～270 parts of Pericarpium Citri Reticulataes
200～270 parts of Rhizoma Cyperis
200～270 parts in Fructus Hordei Germinatus (stir-fry)
200～270 parts of Fructus Crataegis (Jiao)
200～270 parts of Fructus Amomis
100～180 parts in Radix Glycyrrhizae
In the above-mentioned Chinese medicine of respectively distinguishing the flavor of, best formula combination is:
285 parts of Radix Ginsengs
190 parts of the Rhizoma Atractylodis Macrocephalaes (stir-fry)
190 parts in Poria
238 parts of Pericarpium Citri Reticulataes
238 parts of Rhizoma Cyperis
238 parts in Fructus Hordei Germinatus (stir-fry)
238 parts of Fructus Crataegis (Jiao)
238 parts of Fructus Amomis
143 parts in Radix Glycyrrhizae
The preparation method of the intercalation soil particle of above-mentioned children's of the present invention may further comprise the steps:
A: the Rhizoma Atractylodis Macrocephalae (stir-fry), Pericarpium Citri Reticulatae, Rhizoma Cyperi, amomum powder are broken into coarse powder, add the water of 5 times of weight, and steam distillation extracted volatile oil 5 hours, collect volatile oil, and distillation rear solution device is in addition collected;
Medicinal residues and Poria, Fructus Hordei Germinatus (stir-fry), Fructus Crataegi (Jiao), Radix Glycyrrhizae that b: step a extracts behind the volatile oil decoct with water secondary, add for the first time 10 times of water gagings, decocted 2 hours, the water that adds for the second time 6 times of amounts, decocted 1 hour, and merged decoction liquor, filter, the aqueous solution that filtrate and step a extract behind the volatile oil merges, and is condensed into the clear paste that relative density is 1.35-1.38 at 55 ℃;
C: the Radix Ginseng powder is broken into coarse powder, adds 50% alcohol heating reflux and extracts secondary, adds 8 times of amounts for the first time, add for the second time 6 times of amounts, the each extraction 2 hours, merge extractive liquid, filters, filtrate recycling ethanol, be condensed into the clear paste that relative density is 1.35-1.38 at 55 ℃, extract clear paste with the step a Rhizoma Atractylodis Macrocephalae, Poria etc. and merge mixing, drying is ground into dry extract;
D: get 5 times of step a volatilization oil mass cycloheptaamyloses, add 20% ethanol of 2 times of dextrin amounts, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying is pulverized;
E: combining step c obtains the volatile oil encapsulation object dry powder that extract powder and steps d obtain, and fully mixes, and the mixture that adds dextrin and sugar obtains this product as the adjuvant dry granulation.
Wherein, the ratio of sugar and dextrin is 1: 1 in the adjuvant that uses among the step e, and supplementary product consumption is about drug extract powder and volatile oil encapsulation object total amount 1 times.
By the intercalation soil particle of the children's of method for preparing, made full use of the characteristic of the effective ingredient of the medical material of respectively distinguishing the flavor of, taked different extractions and processing method, kept content of effective to greatest extent.With the peoniflorin is index, adopt the HPLC method to measure the amount of the Radix Paeoniae Alba in this preparation, the result shows the amount that can accurately determine the peoniflorin in the preparation with this method mensuration, determine at last to contain the amount of the Radix Paeoniae Alba in peoniflorin in this preparation, the intercalation soil particle specification of children's is every bag of 7g, and this product contains Radix Ginseng with ginsenoside Rg1 (C for every bag
42H
72O
14) and ginsenoside Re (C
48H
82O
18) meter, be no less than 2.7mg.
The specific embodiment
Embodiment 1:
The Rhizoma Atractylodis Macrocephalae (stir-fry) 160g, Pericarpium Citri Reticulatae 200g, Rhizoma Cyperi 200g, Fructus Amomi 200g are ground into coarse powder, add 3600 ml waters, and steam distillation extracted volatile oil 5 hours, collect about 8 milliliters of volatile oil, and distillation rear solution device is in addition collected.
Medicinal residues and Poria 160g, Fructus Hordei Germinatus (stir-fry) 200g, Fructus Crataegi (Jiao) 200g, Radix Glycyrrhizae 100g behind the extraction volatile oil decoct with water secondary, add for the first time 14200 ml waters, decocted 2 hours, add for the second time 8520 milliliters water, decocted 1 hour, and merged decoction liquor, filter, aqueous solution behind filtrate and the extraction volatile oil merges, and 55 ℃ are condensed into the clear paste that relative density is 1.35-1.38.
Radix Ginseng 250g is ground into coarse powder, adds 50% alcohol heating reflux and extracts secondary, adds 2000 milliliters for the first time, for the second time add 1500 milliliters, the each extraction 2 hours, merge extractive liquid, filters, filtrate recycling ethanol, 55 ℃ are condensed into the clear paste that relative density is 1.35-1.38, extract clear paste with the Rhizoma Atractylodis Macrocephalae, Poria etc. and merge mixing, drying is ground into the about 360g of dry extract.
Get the 40g cycloheptaamylose, add 80 milliliter of 20% ethanol, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying is pulverized, and gets the about 46g of encapsulation object.
Above dry extract of combining step and volatile oil encapsulation object dry powder is 406g altogether, fully mixes, and adds the about 594g of mixture (1: 1) of dextrin and sugar, and dry granulation gets granule 1000g, obtains this product.
Embodiment 2:
The Rhizoma Atractylodis Macrocephalae (stir-fry) 220g, Pericarpium Citri Reticulatae 27g, Rhizoma Cyperi 270g, Fructus Amomi 270g are ground into coarse powder, add 4900 ml waters, and steam distillation extracted volatile oil 5 hours, collect about 10.8 milliliters of volatile oil, and distillation rear solution device is in addition collected.
Medicinal residues and Poria 220g, Fructus Hordei Germinatus (stir-fry) 270g, Fructus Crataegi (Jiao) 270g, Radix Glycyrrhizae 180g behind the extraction volatile oil decoct with water secondary, add for the first time 19700 ml waters, decocted 2 hours, add for the second time 11820 ml waters, decocted 1 hour, and merged decoction liquor, filter, aqueous solution behind filtrate and the extraction volatile oil merges, and being condensed into relative density is the clear paste of 1.35-1.38 (55 ℃).
Radix Ginseng 32g is ground into coarse powder, adds 50% alcohol heating reflux and extracts secondary, adds 2560 milliliters for the first time, for the second time add 1920 milliliters, the each extraction 2 hours, merge extractive liquid, filters, filtrate recycling ethanol, being condensed into relative density is the clear paste of 1.35-1.38 (55 ℃), extracts clear paste with the Rhizoma Atractylodis Macrocephalae, Poria etc. and merges mixing, drying is ground into the about 493g of dry extract.
Get the 54g cycloheptaamylose, add 108 milliliter of 20% ethanol, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying, pulverize encapsulation object 62g.
Above dry extract of combining step and volatile oil encapsulation object dry powder is 555g altogether, fully mixes, and the mixture 445g (1: 1) that adds dextrin and sugar makes granule 1000g as the adjuvant dry method, obtains this product.
Embodiment 3:
The Rhizoma Atractylodis Macrocephalae (stir-fry) 190g, Pericarpium Citri Reticulatae 238g, Rhizoma Cyperi 238g, Fructus Amomi 238g are ground into coarse powder, add 4520 ml waters, and steam distillation extracted volatile oil 5 hours, collect about 9.5 milliliters of volatile oil, and distillation rear solution device is in addition collected.
Medicinal residues and Poria 190g, Fructus Hordei Germinatus (stir-fry) 238g, Fructus Crataegi (Jiao) 238g, Radix Glycyrrhizae 143g behind the extraction volatile oil decoct with water secondary, add for the first time 17130 ml waters, decocted 2 hours, add for the second time 10278 ml waters, decocted 1 hour, and merged decoction liquor, filter, aqueous solution behind filtrate and the extraction volatile oil merges, and being condensed into relative density is the clear paste of 1.35-1.38 (55 ℃).
Radix Ginseng 285g is ground into coarse powder, adds 50% alcohol heating reflux and extracts secondary, adds 2280 milliliters for the first time, for the second time add 1710 milliliters, the each extraction 2 hours, merge extractive liquid, filters, filtrate recycling ethanol, being condensed into relative density is the clear paste of 1.35-1.38 (55 ℃), extracts clear paste with the Rhizoma Atractylodis Macrocephalae, Poria etc. and merges mixing, drying is ground into dry extract 430g.
Get the 47.5g cycloheptaamylose, add 95 milliliter of 20% ethanol, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying, pulverize encapsulation object 54.5g.
Above dry extract of combining step and volatile oil encapsulation object dry powder is 484.5g altogether, fully mixes, and the mixture 515.5g (1: 1) that adds dextrin and sugar makes granule 1000g as the adjuvant dry method, obtains this product.
The invention described above obtains the intercalation soil particle of children's except reaching the general prescription of granule.Also active constituent content is measured research: be index with ginsenoside, adopt the HPLC method to measure the amount of Radix Ginseng in this preparation, the result shows the amount that can accurately determine the ginsenoside in the preparation with this method mensuration, determine at last to contain the amount of Radix Ginseng with the ginsenoside in this preparation, the intercalation soil particle specification of children's is every bag of 7g, and every 7g sample particle is with ginsenoside Rg1 (C
42H
72O
14) and ginsenoside Re (C
48H
82O
18) meter, must not be less than 2.75mg.
Stability observing:
3 months reserved sample observing methods are measured the preliminarily stabilised of this preparation, and the result shows that this preparation was stable in 3 months, and its long-time stability await further observation.
The main pharmacodynamics experiment:
Antiinflammatory action: the intercalation soil particle small dose group of children's can significantly suppress the mice auricle swelling that caused by dimethylbenzene.
Analgesic activity: the pain threshold that the big or middle dosage group of the intercalation soil particle of children's can significant prolongation hot plate mice when administration 0.5h, and can significant prolongation acetic acid cause analgesia incubation period of pain mice, that significantly reduces mice turns round the body number of times, and remarkable analgesic activity is arranged.
Effect to intestinal function: the big or middle dosage group of the intercalation soil particle of children's can significantly improve mice charcoal end propelling rate, and big or middle dosage group is absorbed with significant facilitation to the rat small intestine xylose.
Effect to gastric emptying: the large, medium and small dosage group of the intercalation soil particle of children's can significantly increase the gastric emptying ability of mice.
Effect to the gastritis rat model: the large, medium and small dosage group of the intercalation soil particle of children's can significantly reduce the gastric acidity and the gastric juice viscosity of gastritis rat model, dosage group big or middle can significantly reduce the peptic activity of stomach in the gastritis rat model gastric juice, the heavy dose of group of secretory volume that can significantly increase gastrin.
Acute toxicity test:
The intercalation soil particle mice of children's maximum dosage-feeding is 480g/kg, quite and 343 times of people's clinical application amount
Long term toxicity test:
The clinical course of treatment of the intercalation soil particle of children's was two weeks, this experimental observation convalescent period of 2 months long term toxicity of rat continuous use and one month observe.After having observed the long-term gastric infusion of rat, to the toxic reaction that body produced and the degree of reversibility of reaction.The result shows, 2 months whole bodies of rat continuous use do not have the generation of poisoning, rats eating, movable normal, body weight slightly increases, hematology, serum biochemistry are learned relatively no significant difference (p＞0.05) of each index and organ coefficient and matched group, and each medication group internal organs of histopathologic examination and matched group relatively there is no obvious pathomorphology and change.
Claims (5)
1. intercalation soil particle of children's, it is characterized in that: by following Chinese herbal medicine is that raw material makes: Radix Ginseng, the Rhizoma Atractylodis Macrocephalae (stir-fry), Poria, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Fructus Hordei Germinatus (stir-fry), Fructus Crataegi (Jiao), Fructus Amomi, Radix Glycyrrhizae.
2. the intercalation soil particle of children's according to claim 1, it is characterized in that: the part by weight of each Chinese medicine of distinguishing the flavor of is:
250～320 parts of Radix Ginsengs
160～220 parts of the Rhizoma Atractylodis Macrocephalaes (stir-fry)
160～220 parts in Poria
200～270 parts of Pericarpium Citri Reticulataes
200～270 parts of Rhizoma Cyperis
200～270 parts in Fructus Hordei Germinatus (stir-fry)
200～270 parts of Fructus Crataegis (Jiao)
200～270 parts of Fructus Amomis
100～180 parts in Radix Glycyrrhizae
3. the intercalation soil particle of children's according to claim 2, it is characterized in that: the part by weight of each Chinese medicine of distinguishing the flavor of is:
285 parts of Radix Ginsengs
190 parts of the Rhizoma Atractylodis Macrocephalaes (stir-fry)
190 parts in Poria
238 parts of Pericarpium Citri Reticulataes
238 parts of Rhizoma Cyperis
238 parts in Fructus Hordei Germinatus (stir-fry)
238 parts of Fructus Crataegis (Jiao)
238 parts of Fructus Amomis
143 parts in Radix Glycyrrhizae
4. the preparation method of a claim 1, the intercalation soil particle of 2 or 3 described children's is characterized in that may further comprise the steps:
A: the Rhizoma Atractylodis Macrocephalae (stir-fry), Pericarpium Citri Reticulatae, Rhizoma Cyperi, amomum powder are broken into coarse powder, add the water of 5 times of weight, and steam distillation extracted volatile oil 5 hours, collect volatile oil, and distillation rear solution device is in addition collected;
Medicinal residues and Poria, Fructus Hordei Germinatus (stir-fry), Fructus Crataegi (Jiao), Radix Glycyrrhizae that b: step a extracts behind the volatile oil decoct with water secondary, add for the first time 10 times of water gagings, decocted 2 hours, the water that adds for the second time 6 times of amounts, decocted 1 hour, and merged decoction liquor, filter, the aqueous solution that filtrate and step a extract behind the volatile oil merges, and is condensed into the clear paste that relative density is 1.35-1.38 at 55 ℃;
C: the Radix Ginseng powder is broken into coarse powder, adds 50% alcohol heating reflux and extracts secondary, adds 8 times of amounts for the first time, add for the second time 6 times of amounts, the each extraction 2 hours, merge extractive liquid, filters, filtrate recycling ethanol, be condensed into the clear paste that relative density is 1.35-1.38 at 55 ℃, extract clear paste with the step a Rhizoma Atractylodis Macrocephalae, Poria etc. and merge mixing, drying is ground into dry extract;
D: get 5 times of step a volatilization oil mass cycloheptaamyloses, add 20% ethanol of 2 times of dextrin amounts, grind to form pasty state, add above-mentioned volatile oil, ground 2 hours, cold drying is pulverized;
E: combining step c obtains the volatile oil encapsulation object dry powder that extract powder and steps d obtain, and fully mixes, and the mixture that adds dextrin and sugar obtains this product as the adjuvant dry granulation.
5. the preparation method of the intercalation soil particle of children's according to claim 4 is characterized in that: the ratio of sugar and dextrin is 1: 1 in the adjuvant that uses among this step e, and supplementary product consumption is about drug extract powder and volatile oil encapsulation object total amount 1 times.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100425258A CN1292789C (en) | 2004-05-20 | 2004-05-20 | Infant's Runtu granulars and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100425258A CN1292789C (en) | 2004-05-20 | 2004-05-20 | Infant's Runtu granulars and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1579523A true CN1579523A (en) | 2005-02-16 |
| CN1292789C CN1292789C (en) | 2007-01-03 |
Family
ID=34582165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100425258A Expired - Fee Related CN1292789C (en) | 2004-05-20 | 2004-05-20 | Infant's Runtu granulars and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1292789C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103356946A (en) * | 2013-07-30 | 2013-10-23 | 吉林省东北亚药业股份有限公司 | Children's traditional Chinese medicinal preparation for spleen and stomach reinforcing, qi rectifying and stagnation transforming |
| CN104825974A (en) * | 2015-05-28 | 2015-08-12 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating loss of appetite |
| CN105056092A (en) * | 2015-08-21 | 2015-11-18 | 北京汉典制药有限公司 | Preparation method of ginseng, poria cocos and white atractylodes rhizome granules and prepared ginseng, poria cocos and white atractylodes rhizome granules |
| CN111821187A (en) * | 2020-07-28 | 2020-10-27 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine extract powder granulating system and method for treating cervical spondylosis |
| CN114732883A (en) * | 2022-03-02 | 2022-07-12 | 湖南天药堂中医药文化产业发展有限公司 | Traditional Chinese medicine composition for invigorating spleen and benefiting stomach and preparation method and application thereof |
| CN115944699A (en) * | 2022-12-14 | 2023-04-11 | 修正药业集团股份有限公司 | Traditional Chinese medicine composition with effects of activating spleen, tonifying qi, promoting digestion and removing food stagnation as well as preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1155426A (en) * | 1996-10-26 | 1997-07-30 | 迟经惠 | Preparation for the function of spleen |
-
2004
- 2004-05-20 CN CNB2004100425258A patent/CN1292789C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103356946A (en) * | 2013-07-30 | 2013-10-23 | 吉林省东北亚药业股份有限公司 | Children's traditional Chinese medicinal preparation for spleen and stomach reinforcing, qi rectifying and stagnation transforming |
| CN104825974A (en) * | 2015-05-28 | 2015-08-12 | 合肥丰瑞隆生物科技有限公司 | Traditional Chinese medicine for treating loss of appetite |
| CN105056092A (en) * | 2015-08-21 | 2015-11-18 | 北京汉典制药有限公司 | Preparation method of ginseng, poria cocos and white atractylodes rhizome granules and prepared ginseng, poria cocos and white atractylodes rhizome granules |
| CN105056092B (en) * | 2015-08-21 | 2019-05-03 | 北京汉典制药有限公司 | A kind of preparation method of granule containing ginseng, Siberian cocklebur, lagehead atractylodes and its granule containing ginseng, Siberian cocklebur, lagehead atractylodes of preparation |
| CN111821187A (en) * | 2020-07-28 | 2020-10-27 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine extract powder granulating system and method for treating cervical spondylosis |
| CN114732883A (en) * | 2022-03-02 | 2022-07-12 | 湖南天药堂中医药文化产业发展有限公司 | Traditional Chinese medicine composition for invigorating spleen and benefiting stomach and preparation method and application thereof |
| CN114732883B (en) * | 2022-03-02 | 2023-07-25 | 湖南天药堂中医药文化产业发展有限公司 | Traditional Chinese medicine composition for strengthening spleen and tonifying stomach as well as preparation method and application thereof |
| CN115944699A (en) * | 2022-12-14 | 2023-04-11 | 修正药业集团股份有限公司 | Traditional Chinese medicine composition with effects of activating spleen, tonifying qi, promoting digestion and removing food stagnation as well as preparation method and application thereof |
| CN115944699B (en) * | 2022-12-14 | 2024-03-15 | 修正药业集团股份有限公司 | Traditional Chinese medicine composition with effects of activating spleen and tonifying qi, and promoting digestion and resolving stagnation, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1292789C (en) | 2007-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1724040A (en) | Chinese patent drug for treating infantile cold and repeated cold, and its prepn. method | |
| CN100443112C (en) | Medicine for treating gout and gout arthritis | |
| WO2010135858A1 (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN1742903A (en) | Medicine for treating prostatitis and hyperlasia of prostate | |
| CN1292789C (en) | Infant's Runtu granulars and preparation method | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN1695730A (en) | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN101780263A (en) | Traditional Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN103989820A (en) | Medicament for treating hyperlipidemia | |
| CN1943756A (en) | A Chinese traditional medicinal composite used for treatment of hypertension and its preparation method | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN101732657A (en) | Medicine composition | |
| CN108186821B (en) | Traditional Chinese medicine composition for treating nervous headache and preparation method and application thereof | |
| CN1218741C (en) | Fingered citron particals for stomach ailment and its preparing method | |
| CN104083741A (en) | Traditional Chinese medicinal composition for treating chronic gastritis and preparation method thereof | |
| CN105250954A (en) | Traditional Chinese medicine for treating irritable bowel syndrome and preparation method of traditional Chinese medicine | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN101214302A (en) | Pharmaceutical compositions for treating melancholia associated with functional dyspepsia and preparation | |
| CN1363386A (en) | Composition Chinese-medicinal herb pieces and preparing process thereof | |
| CN108404068B (en) | Pharmaceutical composition for treating and/or preventing diarrhea and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG TAIYUAN CHINESE MEDICINE RESEARCH AND DEV Free format text: FORMER OWNER: ZHANG HUIYUN Effective date: 20091225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Shandong city of Tai'an province high tech Zone South Phoenix Road zip code: 271000 Patentee after: Shandong Taiyuan Chinese medicine research and Development Co Ltd Address before: Shandong Province, Qingdao City, Hongkong Road No. 316 Nonghaiyuan block B No. 20 Qingdao Oceanpower the innovation of bio natural medicine research center zip code: 266061 Co-patentee before: Qiao Mingqi Patentee before: Zhang Hui Yun |
|
| ASS | Succession or assignment of patent right |
Owner name: QINGDAO YANGGUANG HAICHUAN PHARMACEUTICAL TECHNOLO Free format text: FORMER OWNER: SHANDONG TAIYUAN TRADITIONAL CHINESE MEDICINE R + D CO., LTD. Effective date: 20101122 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 271000 SOUTH SECTION OF FENGTIAN ROAD, HIGH-TECH. ZONE, TAIAN CITY, SHANDONG PROVINCE TO: 266071 B20, NONGHAIYUAN, NO. 316, XIANGGANG EAST ROAD, LAOSHAN DISTRICT, QINGDAO CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101122 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee after: Qingdao Sunshine Haichuan Medical Technology Development Co.,Ltd. Address before: 271000 Shandong high tech Zone in Tai'an City, Phoenix Road South Patentee before: Shandong Taiyuan Chinese medicine research and Development Co Ltd |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070103 Termination date: 20140520 |